Date | Price Target | Rating | Analyst |
---|---|---|---|
7/25/2024 | $18.50 | Buy | B. Riley Securities |
4/4/2024 | $15.00 | Mkt Outperform | JMP Securities |
1/3/2024 | $15.00 | Equal Weight | Barclays |
2/2/2023 | $30.00 | Buy | B. Riley Securities |
11/1/2022 | $19.00 | Buy | Stifel |
7/15/2022 | $38.00 | Outperform | SVB Leerink |
2/16/2022 | $98.00 → $76.00 | Buy | Lake Street |
11/10/2021 | $67.00 → $100.00 | Outperform | RBC Capital |
B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50
JMP Securities initiated coverage of OptimizeRx with a rating of Mkt Outperform and set a new price target of $15.00
Barclays initiated coverage of OptimizeRx with a rating of Equal Weight and set a new price target of $15.00
10-Q - OptimizeRx Corp (0001448431) (Filer)
8-K - OptimizeRx Corp (0001448431) (Filer)
S-8 POS - OptimizeRx Corp (0001448431) (Filer)
WALTHAM, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced an expansion of a strategic relationship with a major pharma client via a muti-solution, multi-brand program bringing the total in year commitment to over $10 million, which includes the previously mentioned $6 million DAAP contract. This initial program, however, ultimately resulted in a multi-solution, multi-brand engagement while DAAP conversion continues through the client's internal review and approval process. This engagem
The availability of Micro-Neighborhood® Targeting on the Company's Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing OptimizeRx presents panel session at Digital Pharma East: Unlocking Opportunity through HCP+DTC Alignment in Omnichannel Oncology Marketing WALTHAM, Ma., Sept. 09, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and prospective patients, today announces the leading AI-driven marketing technology for healthcare consumers, Micro-Neighborh
– Q2 revenue of $18.8 million, increasing 36% year-over-year– Q2 gross profit increased 50% year-over-year to $11.7 million with a gross margin of 62%– Won 8 DAAP deals during Q2 WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended June 30, 2024. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the second quarter of 2024 increased 36% to $18.8 million, as compared to $13.8 million in the same year ago period
4 - OptimizeRx Corp (0001448431) (Issuer)
3 - OptimizeRx Corp (0001448431) (Issuer)
4 - OptimizeRx Corp (0001448431) (Issuer)
– Q2 revenue of $18.8 million, increasing 36% year-over-year– Q2 gross profit increased 50% year-over-year to $11.7 million with a gross margin of 62%– Won 8 DAAP deals during Q2 WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended June 30, 2024. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the second quarter of 2024 increased 36% to $18.8 million, as compared to $13.8 million in the same year ago period
WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, will hold a conference call on Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2024. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, August 8, 2024Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Q1 revenue of $19.7 million, increasing 51% year-over-yearQ1 gross profit increased 64% year-over-year to $12.2 million with a gross margin of 62%Won 9 DAAP deals during Q1 WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended March 31, 2024. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2024 increased 51% to $19.7 million, as compared to $13.0 million in the same year ago period.Gross profit
SC 13G/A - OptimizeRx Corp (0001448431) (Subject)
SC 13G - OptimizeRx Corp (0001448431) (Subject)
SC 13G/A - OptimizeRx Corp (0001448431) (Subject)
JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:OPRX) with a Market Outperform and maintains $16 price target.
7 analysts have shared their evaluations of OptimizeRx (NASDAQ:OPRX) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 5 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 0 0 0 3M Ago 1 3 0 0 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $15.0, a high estimate of $17.00, and a low estimate of $13.00. Surpassing the previous average
JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:OPRX) with a Market Outperform and maintains $16 price target.
WALTHAM, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, is pleased to announce changes to its Board of Directors reflecting a strategic move to further align with the company's growth plans. After nearly a decade of service, Gus Halas is retiring from his position as Chairperson of the Board. During his tenure, he played a pivotal role in shaping OptimizeRx's success, and we extend our deepest gratitude for his commitment and leadership. Effective immediately, Lynn O'Connor Vos will assume the role o
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy. "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Exec
ROCHESTER, Mich., Sept. 30, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, announced the appointment of Edward Stelmakh as chief financial officer (CFO) and chief operating officer (COO) effective October 11th, 2021. He succeeds Doug Baker within the financial organization, who will continue as executive vice president of finance and accounting. "Ed's extensive financial expertise, operational experience, and business analytics capabilities gained through years of leading the financial and operational teams of multiple growing public pharmaceutical companies